Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Thallion Pharma, a biotechnology company developing pharmaceutical products in the areas of infectious disease and oncology, has reported revenues of $1.3m for the third quarter ended 31 August 2010 compared to $11,951 for the same period in 2009.
Subscribe to our email newsletter
Thallion Pharma has posted a net loss of $351,394 for the third quarter 2010, or $0.01 loss per diluted share, compared to net loss of $3.03m, or $0.09 loss per diluted share, for the comparable period in 2009.
For the nine months ended 31 August 2010 Thallion Pharma has posted a revenue of $2.39m compared to $70,026 for the year ago period.
For the nine months ended 31 August 2010 Thallion Pharma has posted a net loss of $3.75m, or $0.12 loss per diluted share, compared to net loss of $9.26m, or $0.29 loss per diluted share, for the year ago period.
Thallion Pharma CEO Allan Mandelzys said that they were on track to initiate the Phase II Shigamabs trial in South America prior to the end of 2010.
"With a development partner like LFB Biotechnologies providing funding support for the clinical program, we are in a position to drive development forward with sufficient cash-on-hand to manage the trial through to pivotal clinical data," Mandelzys said.